Newly Released Prisoners Are 40 Times More Likely to Overdose Than the General Population

According to a recent study in the American Journal of Public Health.

Kenishirotie/Getty

In the first two weeks after their release, former inmates are 40 times more likely to overdose on opioids than the general population. That’s according to a recent study in the American Journal of Public Health.

Past research has shown that the period immediately following jail or prison is a dangerous time, but this is the first study to examine post-incarceration overdose rates since America’s opioid epidemic took hold. In 2016, more than 64,000 Americans died of overdoses—more than the US military deaths in the Vietnam War.

By some estimates, as many as two-thirds of prisoners have substance abuse disorders. Former inmates with a history of opioid addiction face compounding risks: They have lost their tolerance to opioids, yet the drugs in circulation are far more potent than they were a few years ago—especially since heroin and counterfeit painkillers are often laced with synthetic opioids like fentanyl. “The [drug] market is always changing and evolving,” explained study co-author Dr. Steven Marshall, an epidemiologist who directs the University of North Carolina’s Injury Prevention Research Center. “Some of these people are coming out into a new mix of drugs that weren’t around when they were [in prison].”

Overdoses: Former Inmates vs. General Population

Per 100,000 in North Carolina

The researchers combined two data sets: North Carolina prison releases between 2000 and 2015, and death records through 2016. They found that opioid overdose rates were highest in the two weeks after release but continued to remain high: nearly 11 times higher than the general population in the year after release, and 8 times higher overall.

Despite the sky-high rates of substance use disorders among inmates, only a fraction of prisons offer evidence-based addiction treatment. The most promising approach for opioid addiction is a combination of counseling with one of three medications: methadone, buprenorphine, or naltrexone. A recent Vox investigation found that Rhode Island is the only state to allow prisoners access to all three medications—a policy that has resulted in a dramatic fall in post-incarceration deaths. Sixteen states offered only naltrexone, the least studied of the three medications. The remaining offered no medications at all.

The authors call for the use of buprenorphine and methadone in prisons and distribution of the overdose reversal drug naloxone prior to release. They also note the need for more robust reentry services, as challenges such as finding a job, housing, or health care—particularly in states like North Carolina, which didn’t expand Medicaid under the Affordable Care Act—could “serve as an impetus for substance abuse.”

“Just as it is important to target high-risk populations in infectious disease epidemics, our society must find additional ways to prevent opioid-related [overdoses] among former inmates,” the study concludes. “Overall, imprisonment for individuals with substance use disorder may be more harmful than helpful.”

FACT:

Mother Jones was founded as a nonprofit in 1976 because we knew corporations and the wealthy wouldn't fund the type of hard-hitting journalism we set out to do.

Today, reader support makes up about two-thirds of our budget, allows us to dig deep on stories that matter, and lets us keep our reporting free for everyone. If you value what you get from Mother Jones, please join us with a tax-deductible donation today so we can keep on doing the type of journalism 2019 demands.

We Recommend

Latest

Give a Year of the Truth

at our special holiday rate

just $12

Order Now

Sign up for our newsletters

Subscribe and we'll send Mother Jones straight to your inbox.

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate

We have a new comment system! We are now using Coral, from Vox Media, for comments on all new articles. We'd love your feedback.